argenx SE (EBR:ARGX)
Belgium · Delayed Price · Currency is EUR | Market Cap | 49.84B +67.3% |
| Revenue (ttm) | 4.65B +70.3% |
| Net Income | 1.50B +33.9% |
| EPS | 22.95 +39.8% |
| Shares Out | 62.54M |
| PE Ratio | 34.74 |
| Forward PE | 28.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,171 |
| Open | 799.00 |
| Previous Close | 797.00 |
| Day's Range | 798.00 - 826.20 |
| 52-Week Range | 489.90 - 833.60 |
| Beta | -0.02 |
| Analysts | Strong Buy |
| Price Target | 885.89 (+7.38%) |
| Earnings Date | Jul 23, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price target is €885.89, which is an increase of 7.38% from the latest price.
News
Argenx price target raised to $1,065 from $955 at Leerink
Leerink raised the firm’s price target on Argenx (ARGX) to $1,065 from $955 and keeps an Outperform rating on the shares.
Argenx price target raised to $1,185 from $1,135 at Guggenheim
Guggenheim raised the firm’s price target on Argenx (ARGX) to $1,185 from $1,135 and keeps a Buy rating on the shares. Global Vyvgart sales came in as “a clear beat”…
Argenx price target raised to $1,350 from $1,291 at Wells Fargo
Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,350 from $1,291 and keeps an Overweight rating on the shares. The firm says Vyvgart’s Q2 beat and management’s…
Argenx price target lowered to $932 from $944 at Citizens
Citizens lowered the firm’s price target on Argenx (ARGX) to $932 from $944 and keeps an Outperform rating on the shares. Argenx delivered stronger-than-expected Q2 results, with continued VYVGART gro...
Argenx price target raised to $1,025 from $945 at RBC Capital
RBC Capital raised the firm’s price target on Argenx (ARGX) to $1,025 from $945 and keeps an Outperform rating on the shares after the company reported Q2 results. Vyvgart was…
argenex Q2 Earnings Call Highlights
argenex NASDAQ: ARGX reported what executives described as one of its strongest quarters to date, driven by continued growth for VYVGART across myasthenia gravis and chronic inflammatory demyelinating...
argenx SE Earnings Call Transcript: Q2 2026
Q2 2026 saw record revenue growth of 60% year-over-year, driven by VYVGART's strong performance in MG and CIDP, including the seronegative MG launch. Pipeline progress and label expansions are set to sustain long-term growth, with robust financials and disciplined capital allocation.
argenx SE Earnings release: Q2 2026
argenx SE released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
argenx SE Slides: Q2 2026
argenx SE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Argenx Q2 Sales Jump 60%; Expects Multiple Readouts Ahead For VYVGART And Empasiprubart; Stock Up
(RTTNews) - argenx SE (ARGX), an immunology company, announced second-quarter results reflecting profit improvement backed by VYVGART's 60% sales growth.
argenx SE (ARGX) Reports Strong Q2 Earnings with Significant Revenue Growth
argenx SE (ARGX) Reports Strong Q2 Earnings with Significant Revenue Growth
Argenx's Vyvgart sales jump in second quarter
Belgian-Dutch immunology company argenx said on Thursday global sales of its lead drug Vyvgart jumped in the second quarter of 2026 from a year earlier.
Pre-Market Earnings Report for July 23, 2026 : RTX, TMUS, TMO, TTE, UNP, LMT, BX, FCX, CMCSA, NSC, HON, ARGX
The following companies are expected to report earnings prior to market open on 07/23/2026. Visit our Earnings Calendar for a full list of expected earnings releases.RTX Corporation (RTX)is reporting ...
ARGX Maintained by Citigroup -- Price Target Raised to $1182
ARGX Maintained by Citigroup -- Price Target Raised to $1182
Argenx price target raised to $1,182 from $1,152 at Citi
Citi raised the firm’s price target on Argenx (ARGX) to $1,182 from $1,152 and keeps a Buy rating on the shares. The firm cites a higher probability-of-success for the Phase…
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it...
Chai Discovery Enters Into Collaboration Agreement With argenx to Advance AI-Driven Immunology Breakthroughs
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration agreement with argenx, a leading immunology innovat...
ARGX Maintained by RBC Capital -- Price Target Raised to $945
ARGX Maintained by RBC Capital -- Price Target Raised to $945
Argenx price target raised to $945 from $890 at RBC Capital
RBC Capital raised the firm’s price target on Argenx (ARGX) to $945 from $890 and keeps an Outperform rating on the shares as part of a broader research note previewing…
Argenx price target raised to EUR 900 from EUR 750 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Argenx (ARGX) to EUR 900 from EUR 750 and keeps a Buy rating on the shares. The firm expects myositis “to work…
ARGX Maintains Rating by B of A Securities -- Price Target Raised to $1088
ARGX Maintains Rating by B of A Securities -- Price Target Raised to $1088
Argenx price target raised to $1,088 from $1,016 at BofA
BofA raised the firm’s price target on Argenx (ARGX) to $1,088 from $1,016 and keeps a Buy rating on the shares. Following the company’s recent Myositis Investor Event, the firm…
Argenx, Stock Of The Day, Eyes Buy Point Amid Triple-Digit Growth
Wells Fargo on Wednesday named the biotech stock a top Q3 tactical pick. An important catalyst looms for Argenx stock.
Argenx (ARGX) Gains Spotlight as Wells Fargo Targets $100B Valuation
Argenx (ARGX) Gains Spotlight as Wells Fargo Targets $100B Valuation
Argenx added to Q3 Tactical Ideas List at Wells Fargo
Wells Fargo is adding Argenx (ARGX) to the firm’s Q3 Tactical Ideas List. Wells believes Argenx is the next $100B biotech, with a favorable setup into Vyvgart’s Phase 3 myositis…